This article was originally published in The Tan Sheet
Executive Summary"Do not make claims that your products (or any specific product) is good for the treatment or cure of any disease condition...unless the product bears an appropriate health claim," a new version of the NNFA FDA Handbook for Retailers states. A revised version of the handbook, which includes important information pertaining to the Bioterrorism Act of 2002, was released Jan. 17 by the National Nutritional Foods Association. The publication is designed to help food and health product retailers, including those that sell dietary supplements, determine their rights and obligations during an FDA inspection. For example, FDA is not allowed to inspect a retail location without the presence of an establishment representative, according to the guide. The handbook also makes note of what nutritional information retailers can provide to consumers concerning their products. NNFA members can access the handbook free of charge via the NNFA website; non-members can order the publication through the association's online store...
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.